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Drug resistance poses a signiﬁcant challenge in antifungal therapy since resistance has
been found for all known classes of antifungal drugs.The discovery of compounds that can
act synergistically with antifungal drugs is an important strategy to overcome resistance.
For such combination therapies to be effective, it is critical to understand the molecular
basis for the synergism by examining the cellular effects exerted by the combined drugs.
Genomic proﬁling technologies developed in the model yeast Saccharomyces cerevisiae
have been successfully used to investigate antifungal combinations.This review discusses
how these technologies have been used not only to identify synergistic mechanisms but
alsotopredictdrugsynergies.Italsodiscusseshowgenome-widegeneticinteractionstud-
ies have been combined with drug–target information to differentiate between antifungal
drug synergies that are target-speciﬁc versus those that are non-speciﬁc.The investigation
of the mechanism of action of antifungal synergies will undoubtedly advance the develop-
ment of optimal and safe combination therapies for the treatment of drug-resistant fungal
infections.
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INTRODUCTION
Currently available antifungal drugs belong to four major drug
classes: polyenes (e.g., amphotericin B), azoles (e.g., ﬂucona-
zole), echinocandins (e.g., caspofungin), and pyrimidine analogs
(e.g., 5-ﬂuorocytosine; reviewed in Petrikkos and Skiada, 2007;
Pasqualotto and Denning,2008;Denning and Hope,2010). These
drug classes disrupt membrane integrity, ergosterol biosynthesis,
cell wall function, and DNA synthesis respectively. While they
are used extensively in the clinic, the drugs within each class
sufferfromvariouslimitationsincludingtoxicity(polyenes),resis-
tance (azoles), narrow spectrum of activity (echinocandins), and
lack of efﬁcacy as a single agent (5-ﬂuorocytosine). Drug resis-
tance in particular has been a major concern for the fungistatic
azole drugs and also more recently for echinocandins such as
caspofungin (reviewed in Sanglard, 2002; Maertens, 2004; Per-
lin, 2007). In fact, drug resistance has been found for all known
drug classes and poses a signiﬁcant challenge in antifungal ther-
apy (reviewed in Pemán et al., 2009; Mukherjee and Wang, 2010).
One of the ways to overcome drug resistance is by administer-
ing combination therapy. Combination treatments offer several
advantages including the ability to (i) reduce doses, and there-
fore reduce toxicity, (ii) increase spectrum of activity, and (iii)
convert a fungistatic drug to a fungicidal drug, thereby facil-
itating clearance of the pathogen and decreasing the chance
for the development of resistance (reviewed in Johnson et al.,
2004; Mukherjee et al., 2005). Several studies, including work
from our group, have shown the ability of various compounds,
many of which are natural products, to improve the activity of
azole antifungal drugs (e.g., Jacob et al., 2003; Onyewu et al.,
2003; Niimi et al., 2004; Li et al., 2006; Digirolamo et al., 2009;
Pfaller et al., 2009; Ahmad et al., 2010; Gamarra et al., 2010;
Sharma et al., 2010; Wei et al., 2011). However, for the devel-
opment of an effective drug combination regimen,it is important
to understand the molecular mechanism behind the combined
drug effect. Such an understanding will not only be invaluable
in predicting adverse drug interactions and toxic side-effects, but
will also be useful in developing chemical probes for explor-
ing biological pathways targeted by the drug combination. This
review focuses on chemogenomic proﬁling and genetic interac-
tion technologies developed in the model yeast Saccharomyces
cerevisiae, and discusses the applications of these technologies
in predicting drug synergies, elucidating drug synergy mecha-
nisms, and differentiating between speciﬁc and non-speciﬁc drug
synergies.
PREDICTING ANTIFUNGAL SYNERGIES
Jansen et al. (2009) have developed a bioinformatics-driven
approach that predicts synergy between antifungal drug combi-
nations. Their approach makes use of chemogenomic proﬁling,
a technology in which the cellular response to inhibitory com-
pounds is measured by evaluating the ﬁtness of a library of
genome-wide deletion mutant strains. Strains with reduced ﬁt-
ness in the presence of a compound are identiﬁed, and the genes
deleted in those strains provide information on cellular pathways
targeted by the compound as well as pathways that are required
for conferring sensitivity to that compound. Given the availability
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of several whole-genome mutant collections in the model yeast
S. cerevisiae, a large number of chemogenomic proﬁles have been
generated for a variety of compounds in this organism (reviewed
in Agarwal et al., 2008; Hoon et al., 2008b; Ho et al., 2011). These
proﬁleshavebeengeneratedusingdifferentmethods,twoofwhich
are shown in Figure 1. In the ﬁrst method, growth of each indi-
vidual mutant is monitored in the presence or absence of a drug
inamicroplateformat.Inthesecondmethod,pooledmutantsare
analyzed in a single culture, in the presence or absence of a drug.
Survival of the mutant strains is assessed by PCR ampliﬁcation
of unique tags associated with each mutant, and tag abundance
is measured using a DNA microarray carrying complementary
sequences to the tags. The ratio of signals between drug-treated
and untreated samples gives an indication of the relative ﬁtness of
each mutant.
In a large study conducted by Parsons et al. (2006), chemoge-
nomic proﬁles were generated for 82 different compounds, and it
was shown that compounds with similar chemogenomic proﬁles
hadsimilaritiesintheirmodesof action.Toextendthisconceptto
synergistic compounds, Jansen et al. (2009) investigated whether
such proﬁles can be used to predict synergy by assessing if com-
pound pairs with similar proﬁles are more likely to be synergistic
(Figure1).Theauthorscompiledchemogenomicproﬁlesfromthe
literaturefor∼1300genome-widescreensconductedwithabroad
range of compounds, and deﬁned a set of hypersensitive genes
for each compound. The authors also generated a chemogenomic
FIGURE1|P r edicting drug synergies and determining synergy
mechanisms. Chemogenomic proﬁling is conducted by screening drugs
against collections of yeast deletion mutants. For analyzing individual
mutants, the collection is arrayed in microplates, and the growth of each
strain is examined in the presence or absence of the drug. For analyzing
pooled mutants, the collection is grown in a single culture, with or without
drug, and growth is measured by monitoring the abundance of unique tags
associated with each mutant, using DNA microarrays consisting of tag
complements.Two drugs with similar chemogenomic proﬁles would be
predicted to exhibit a synergistic interaction (for simplicity, exactly
matching proﬁles are depicted). If the combination of two synergizing
drugs generates a unique chemogenomic proﬁle of sensitive mutants,
then genes deleted in those mutants provide information on the drug
synergy mechanism.
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proﬁle for the antifungal drug ﬂuconazole, and gene deletions
that were lethal in the presence of ﬂuconazole were identiﬁed.
Then, in order to determine if the chemogenomic proﬁle of any
givencompoundwassimilartothatofﬂuconazole,pairwiseproﬁle
comparisons were made to assess correlations between the hyper-
sensitive gene sets. This analysis identiﬁed eight compounds that
werepredictedtobesynergisticwithﬂuconazole.Theseeightcom-
pounds were then tested experimentally in dose–matrix response
assays, and ﬁve compounds were indeed found to be synergistic
with ﬂuconazole. Interestingly, it was also found that compounds
predicted to be synergistic with ﬂuconazole were also predicted
to be synergistic with each other. These were also tested in dose–
matrix assays, and six compound pairs were identiﬁed that were
synergistic, four of which had not been previously reported. To
extendtheirstudiestoafungalpathogen,theauthorsalsoanalyzed
thedrugpairsinCandidaalbicans,andfoundthateightsynergistic
combinations identiﬁed in S. cerevisiae were also synergistic in C.
albicans. Finally, one of the novel synergistic combinations (ﬂu-
conazole+wortmannin)wasalsotestedinaﬂuconazole-resistant
clinical isolate of C. albicans. This combination was strongly syn-
ergistic in the clinical isolate – it not only inhibited cell growth
in liquid broth, but it was also fungicidal since the cells were not
viable in a recovery assay on agar plates. Thus, this method suc-
cessfully predicted antifungal synergies, and also identiﬁed novel
drug relationships. In addition, S. cerevisiae resources were effec-
tive in identifying synergies in C. albicans. This method will serve
as a powerful tool in the discovery of new synergistic drugs and in
evaluating the potential of combination therapies.
DETERMINING THE MECHANISM BEHIND ANTIFUNGAL
SYNERGIES
In addition to predicting drug synergies, chemogenomic proﬁles
canalsobeusedtoevaluatetheunderlyingmechanismsinvolvedin
the effects produced by synergistic drug combinations. As shown
in Figure 1, for any given synergistic drug pair, chemogenomic
proﬁling can be conducted on cells treated with each drug sepa-
rately and also on cells treated with both drugs simultaneously. If
a unique proﬁle is obtained in the presence of both drugs, then
gene deletions represented in that proﬁle provide information on
the pathways affected or targeted by the drug combination. An
excellent example of the application of this strategy is the study by
Hoonetal.(2008a)inwhichtheauthorsinvestigatedthesynergis-
tic effects of the phosphatase inhibitors cantharidin and calyculin
A.Chemogenomicproﬁlingwasperformedinthepresenceofdilu-
ent only, cantharidin, calyculin A, and a cocktail of cantharidin
and calyculin A. Comparison of the proﬁles obtained indicated
that fewer deletion strains were sensitive to the cocktail,and more
importantly, additional new strains were detected as susceptible
to the cocktail treatment that were not susceptible to the single
drug treatments. The pathways represented in these gene dele-
tions included golgi vesicle transport,chromatin remodeling,and
mRNA polyadenylation. Thus,this study identiﬁed new pathways
required for buffering the effects of the combined treatment of
cantharidin and calyculin A.
Anotherexampleinwhichchemogenomicproﬁlingwasusedto
discover synergistic drug mechanisms is the study by Spitzer et al.
(2011). In this study, six compounds were identiﬁed that showed
synergistic interaction with the antifungal drug ﬂuconazole. To
understand the molecular basis for this synergy, the authors gen-
erated chemogenomic proﬁles for ﬂuconazole and also for each
compound separately. Strains with deletions in genes required
for ergosterol biosynthesis (the pathway targeted by azole anti-
fungals),vesicle-mediated transport,and membrane organization
were sensitive to ﬂuconazole alone. Of the six compounds ana-
lyzed, ﬁve inhibited the growth of strains carrying deletions in
genesinvolvedinmembranefunction,vesicletrafﬁcking,andlipid
biosynthesis, suggesting that these ﬁve compounds cause general
membrane perturbation. Thus, these compounds may exert their
synergistic effect on ﬂuconazole by altering its import or export,
or they may impair the import of exogenous ergosterol. The
chemogenomic proﬁle of the sixth compound analyzed indicated
that it interfered with sphingolipid biosynthesis, thus suggesting
an interplay between the ergosterol and sphingolipid biosynthetic
pathways. Based on this result, the authors also tested myriocin,
another sphingolipid biosynthesis inhibitor,and found that myri-
ocin also showed synergistic activity with ﬂuconazole. Thus, this
study shows that understanding the mechanism behind drug syn-
ergies can be useful in predicting new synergistic interactions. In
addition,byrevealingthatmembranedisruptersandsphingolipid
biosynthesis inhibitors can potentiate ﬂuconazole activity, this
study opens up new avenues for the discovery of novel strategies
for antifungal therapy.
In addition to chemogenomics,other“omics”-based technolo-
gies such as transcriptomics, proteomics, and metabolomics that
measure mRNAs, proteins, and metabolites respectively, can also
be used for mechanistic studies on synergistic compounds. For
example, gene expression proﬁling with the anti-microtubule
agents docetaxel and estramustine in prostate cancer cells iden-
tiﬁed new genes affected by both drugs which were not altered
by each drug alone (Li et al., 2005). Proteomic analysis in C.
albicans with ﬂuconazole and berberine revealed that their syner-
gistic interaction is related to increased generation of endogenous
reactive oxygen species (Xu et al., 2009). Metabolomic proﬁling
to investigate the synergistic anti-leukemic activity of the lipid-
lowering drug bezaﬁbrate and the contraceptive steroid medrox-
yprogesterone acetate identiﬁed changes in TCA cycle interme-
diates, supporting the previously known association of reactive
oxygen species in the anti-tumor activities of these two drugs
(Tiziani et al., 2009). These studies validate the usefulness of
genome-wideproﬁlingapproachesinelucidatingthemechanisms
of drug synergies.
DIFFERENTIATING BETWEEN SPECIFIC AND NON-SPECIFIC
DRUG SYNERGIES
I nar e c e n ts t u d y( Cokol et al., 2011), the genetic basis of antifun-
gal synergies was explored by evaluating the relationship between
synergistic drug interactions and synergistic genetic interactions.
Inasynergisticgeneticinteraction,thecombinationoftwogenetic
perturbations creates a more severe phenotype compared to the
single perturbation alone (Tong et al., 2004). Cokol et al. hypoth-
esized that if two genes have a synergistic genetic interaction,then
two drugs that target those genes may exhibit a synergistic drug
interaction. This prediction would be consistent with the“parallel
pathway inhibition model,” according to which two drugs would
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besynergisticif theyinhibittwoproteinsinparallelpathways(Yeh
et al.,2009). For example,terbinaﬁne and rapamycin exhibit drug
synergyduetoasynergisticgeneticinteractionbetweentheirtarget
genes,ERG1 and TOR1 respectively (Lehár et al.,2007).
In the Cokol et al. study, a comprehensive analysis was con-
ductedtoestablishtheoverlapbetweendrugsynergiesandgenetic
synergies. The authors ﬁrst compiled a list of 113 known drug–
target interactions in S. cerevisiae from the literature, i.e., a list
of known drugs and the target genes affected by those drugs was
generated (Figure 2). This list was then integrated with known
synergistic genetic interactions in this organism. Genetic interac-
tion proﬁles for approximately 75% of all genes in S. cerevisiae
have been generated using the synthetic genetic array (SGA) tech-
nology (Costanzo et al., 2010). In SGA analysis (Figure 2), a
query mutation is crossed into a set of ∼5000 viable deletion
mutants and the resulting double mutants are screened for ﬁt-
ness defects (Tong et al.,2004;Baryshnikova et al.,2010;Costanzo
et al., 2010). Using the available information from several SGA
studies, Cokol et al. (2011) identiﬁed gene pairs that exhibited
severe ﬁtness defects, and examined if these genes were present
in their list of 113 known drug–target interactions. This analy-
sis generated 211 drug pairs that were predicted to be synergistic.
Of these, 38 drug pairs were assessed in dose–matrix response
assays, and 14 drug pairs predicted to be synergistic did indeed
show signiﬁcant synergy in the assays. These drug pairs thus dis-
played“speciﬁc synergy”since genetic interaction proﬁles of their
targetedgenessuggestedthatthedrugswouldtargetparallelpath-
ways (Figure 2). In contrast, several drug pairs (33% of the drug
pairs analyzed) that were not predicted to target synergistic gene
productswerealsofoundtoshowsynergy,thusrepresentingdrugs
displaying “non-speciﬁc synergy” (Figure 2). A set of six drugs
wereidentiﬁedthatwereclassiﬁedaspromiscuoussynergizersthat
were responsible for 92% of all the synergies discovered. This set
included four drugs that target the biosynthesis of ergosterol, a
cell membrane lipid,thus showing consistency with the“bioavail-
ability model” of drug synergy in which one drug’s action affects
the second drug’s availability in the cell (Zimmermann et al.,
2007).Theremainingtwopromiscuoussynergizersarenotknown
to disrupt the cell membrane, suggesting that their promiscuity
involves a novel mechanism. Interestingly, the predominant form
of drug synergy in this study was promiscuous synergy. There-
fore, promiscuous drugs that enhance the potency of other drugs
would have potential value in driving the search for new synergis-
tic drug combinations. However, from a therapeutic standpoint,
drug combinations that are speciﬁc to particular pathways would
beattractivesincetheywouldproducelesstoxicside-effects.Thus,
the ability to differentiate between speciﬁc and promiscuous syn-
ergizerswillclearlyplayanimportantroleinthediscoveryofnovel
combination therapies.
CONCLUDING REMARKS
Chemogenomic proﬁling and genetic interaction studies have
proven to be powerful technologies in investigating the molec-
ular and genetic basis of synergistic drug relationships. However,
it should be noted that just like any other whole-genome technol-
ogy,these technologies suffer from a few drawbacks. For example,
one of the weaknesses of SGA technology is that since it primarily
involves crosses between two haploid mutants, it generally inter-
rogates only non-essential genes. For chemogenomic proﬁling,
analysis of individual mutants in microplate format requires large
quantitiesofdrug,whichcanbealimitationwhenstudyingnatural
products. While chemogenomic proﬁling of pooled mutants, in
whichtagabundanceismonitoredusingDNAmicroarrays,makes
useof smallerquantitiesof drug,thedisadvantageisthehighcost,
the need for DNA microarray facilities, and potential errors in
some tags making them undetectable upon hybridization. With
regards to using chemogenomic proﬁling in predicting drug syn-
ergies, it is worth noting that an identical chemogenomic proﬁle
FIGURE 2 | Differentiating between speciﬁc and non-speciﬁc drug
synergies. Comparing drug–target interactions with synthetic genetic
interactions provides information on speciﬁc and non-speciﬁc drug synergies.
For example, Drug 1 and Drug 3 exhibit speciﬁc synergy since the genes
targeted by them (Gene A and Gene C) genetically interact with each other.
On the other hand, Drug 1 and Drug 2 exhibit non-speciﬁc synergy since there
is no genetic interaction between the genes targeted by them (Gene A and
Gene B). Finally, an example is shown of two drugs (Drug 1 and Drug 4) that
do not synergize with each other, and also do not show any genetic
interaction between the genes they target (Gene A and Gene D).
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for two drugs does not automatically guarantee that there will be
synergy. If two drugs target the same pathway, synergy may not
be likely to occur – for example, sulfamethoxazole and trimetho-
primdonotshowanysynergyinEscherichiacoli eventhoughboth
drugs target the same folate metabolism pathway (reviewed in Jia
etal.,2009).Inspiteof theselimitations,thevariousexamplesdis-
cussed in this review do indeed demonstrate that chemogenomic
proﬁling and SGA technologies have led to greater mechanistic
understandingof synergisticdruginteractionsandhavebeenuse-
fulinpredictingdrugsynergies,andalsoindistinguishingspeciﬁc
synergies from non-speciﬁc ones. The availability of similar tech-
nologies in fungal pathogens such as C. albicans and Cryptococcus
neoformans will of great value in studying drug combinations
in clinically relevant isolates. Given the ever-growing problem of
drug resistance, continued investigations in drug synergy mech-
anisms are greatly needed for the discovery and development of
new combination therapies for treating fungal infections.
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